SC
JAZZ icon

Savant Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Savant Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
4,776
+273
+6% +$59.8K ﹤0.01% 821
2026
Q1 		$851K Buy
4,503
+461
+11% +$80.6K ﹤0.01% 683
2025
Q4 		$687K Buy
4,042
+797
+25% +$122K ﹤0.01% 708
2025
Q3 		$428K Buy
+3,245
New +$389K ﹤0.01% 859
2025
Q2 		– Sell
-2,684
Closed -$333K – 1253
2025
Q1 		$333K Buy
2,684
+476
+22% +$62.1K ﹤0.01% 801
2024
Q4 		$272K Buy
+2,208
New +$260K ﹤0.01% 1158
2024
Q2 		– Sell
-12,462
Closed -$1.5M – 1308
2024
Q1 		$1.5M Buy
+12,462
New +$1.53M 0.02% 425

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Savant Capital's JAZZ Position: Q2 2026 in Review

Savant Capital increased its Jazz Pharmaceuticals (JAZZ) stake by 6.1% in Q2 2026, buying an estimated $59.8K and bringing the position to 4,776 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #821.

Savant Capital first reported a position in JAZZ in Q1 2024 and has held it in 7 quarters since. The position peaked at $1.5M in Q1 2024. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Savant Capital held 4,776 shares of Jazz Pharmaceuticals worth $1.16M as of Q2 2026.
  • Savant Capital bought 273 Jazz Pharmaceuticals shares in Q2 2026, an estimated $59.8K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #821 holding.
  • Savant Capital first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • Savant Capital's Jazz Pharmaceuticals position peaked at $1.5M in Q1 2024.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.